Tags

Type your tag names separated by a space and hit enter

Progression of hair loss in men with androgenetic alopecia (male pattern hair loss): long-term (5-year) controlled observational data in placebo-treated patients.
Eur J Dermatol. 2008 Jul-Aug; 18(4):407-11.EJ

Abstract

Relatively little is known about the progression of androgenetic alopecia (AGA; male pattern hair loss) in untreated men. We evaluated the long-term (5-year) progression of AGA in men treated with placebo in a controlled clinical trial setting. We analyzed pooled data over 5 years from two replicate studies with finasteride 1 mg/day in men with predominantly vertex-pattern AGA. Each study consisted of an initial 1-year, randomized, double-blind, placebo-controlled base study and four consecutive, 1-year, double-blind, placebo-controlled extension studies. Change over time in scalp hair growth was evaluated by four predefined endpoints: scalp hair counts; assessment of standardized clinical photographs by an expert panel; investigator clinical assessment; and patient self-assessment. All four predefined endpoints demonstrated progressive scalp hair loss in men receiving placebo over the 5-year study period, with a loss of 239 hairs from baseline (26.3% decline in hair density) measured in the target area at 5 years (p < 0.001 vs. baseline). Similarly, visible progression of scalp hair loss was demonstrated by global photographic assessment, with 75% of placebo patients rated as worsened from baseline at 5 years. We found that scalp hair loss continued in a progressive manner over a 5-year period in placebo-treated men with AGA.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Kaufman KD
Merck Research Laboratories, Rahway, NJ 07065, USA. keith_kaufman@merck.com
Girman CJ
No affiliation info available
Round EM
No affiliation info available
Johnson-Levonas AO
No affiliation info available
Shah AK
No affiliation info available
Rotonda J
No affiliation info available

MeSH

AdolescentAdultAlopeciaDermatologic AgentsDisease ProgressionDouble-Blind MethodFinasterideHairHumansMalePlacebos

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18573713

Citation

Kaufman, Keith D., et al. "Progression of Hair Loss in Men With Androgenetic Alopecia (male Pattern Hair Loss): Long-term (5-year) Controlled Observational Data in Placebo-treated Patients." European Journal of Dermatology : EJD, vol. 18, no. 4, 2008, pp. 407-11.
Kaufman KD, Girman CJ, Round EM, et al. Progression of hair loss in men with androgenetic alopecia (male pattern hair loss): long-term (5-year) controlled observational data in placebo-treated patients. Eur J Dermatol. 2008;18(4):407-11.
Kaufman, K. D., Girman, C. J., Round, E. M., Johnson-Levonas, A. O., Shah, A. K., & Rotonda, J. (2008). Progression of hair loss in men with androgenetic alopecia (male pattern hair loss): long-term (5-year) controlled observational data in placebo-treated patients. European Journal of Dermatology : EJD, 18(4), 407-11. https://doi.org/10.1684/ejd.2008.0435
Kaufman KD, et al. Progression of Hair Loss in Men With Androgenetic Alopecia (male Pattern Hair Loss): Long-term (5-year) Controlled Observational Data in Placebo-treated Patients. Eur J Dermatol. 2008 Jul-Aug;18(4):407-11. PubMed PMID: 18573713.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Progression of hair loss in men with androgenetic alopecia (male pattern hair loss): long-term (5-year) controlled observational data in placebo-treated patients. AU - Kaufman,Keith D, AU - Girman,Cynthia J, AU - Round,Elizabeth M, AU - Johnson-Levonas,Amy O, AU - Shah,Arvind K, AU - Rotonda,Jennifer, Y1 - 2008/06/23/ PY - 2008/02/13/accepted PY - 2008/6/25/pubmed PY - 2008/12/17/medline PY - 2008/6/25/entrez SP - 407 EP - 11 JF - European journal of dermatology : EJD JO - Eur J Dermatol VL - 18 IS - 4 N2 - Relatively little is known about the progression of androgenetic alopecia (AGA; male pattern hair loss) in untreated men. We evaluated the long-term (5-year) progression of AGA in men treated with placebo in a controlled clinical trial setting. We analyzed pooled data over 5 years from two replicate studies with finasteride 1 mg/day in men with predominantly vertex-pattern AGA. Each study consisted of an initial 1-year, randomized, double-blind, placebo-controlled base study and four consecutive, 1-year, double-blind, placebo-controlled extension studies. Change over time in scalp hair growth was evaluated by four predefined endpoints: scalp hair counts; assessment of standardized clinical photographs by an expert panel; investigator clinical assessment; and patient self-assessment. All four predefined endpoints demonstrated progressive scalp hair loss in men receiving placebo over the 5-year study period, with a loss of 239 hairs from baseline (26.3% decline in hair density) measured in the target area at 5 years (p < 0.001 vs. baseline). Similarly, visible progression of scalp hair loss was demonstrated by global photographic assessment, with 75% of placebo patients rated as worsened from baseline at 5 years. We found that scalp hair loss continued in a progressive manner over a 5-year period in placebo-treated men with AGA. SN - 1167-1122 UR - https://www.unboundmedicine.com/medline/citation/18573713/Progression_of_hair_loss_in_men_with_androgenetic_alopecia__male_pattern_hair_loss_:_long_term__5_year__controlled_observational_data_in_placebo_treated_patients_ DB - PRIME DP - Unbound Medicine ER -